Home » AstraZeneca to Pay $11 Million to Settle Toprol-XL Antitrust Claims
AstraZeneca to Pay $11 Million to Settle Toprol-XL Antitrust Claims
AstraZeneca Pharmaceuticals agreed to pay $11 million to settle claims by a proposed class of indirect purchasers of hypertension drug Toprol-XL that the drugmaker used sham patent litigation to prolong a monopoly on the drug by delaying generic versions.
Law360
Law360
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May